References

Myocardial reperfusion injury: looking beyond primary PCI

10.1093/eurheartj/eht090 · 2013 · External reference

Myocardial ischemia-reperfusion injury: a neglected therapeutic target

10.1172/jci62874 · 2013 · External reference

Glucose for the heart

10.1161/01.cir.99.4.578 · 1999 · External reference

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

10.1016/s0167-0115(03)00125-3 · 2003 · External reference

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

10.1159/000201231 · 1995 · External reference

GLP-1 therapy: beyond glucose control

10.1161/circheartfailure.108.810887 · 2008 · External reference

Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element

10.2337/diabetes.49.7.1156 · 2000 · External reference

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

1997 · External reference

The physiology of glucagon-like peptide 1

10.1152/physrev.00034.2006 · 2007 · External reference

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody

10.1210/en.2013-1934 · 2014 · External reference

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

10.1038/nm.3128 · 2013 · External reference

Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway

10.1007/s10557-007-6030-6 · 2007 · External reference

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor

10.1210/en.2009-1197 · 2010 · External reference

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

10.2337/diab.44.9.1126 · 1995 · External reference

Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes

10.1152/ajpheart.00885.2010 · 2011 · External reference

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

10.1161/circulationaha.107.739938 · 2008 · External reference

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

10.2337/diabetes.54.1.146 · 2005 · External reference

Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model

10.1007/s10557-005-6892-4 · 2005 · External reference

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

10.1161/01.cir.0000139339.85840.dd · 2004 · External reference

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

10.1124/jpet.104.073890 · 2005 · External reference

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

10.1371/journal.pone.0023570 · 2011 · External reference

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

10.1186/1479-5876-11-84 · 2013 · External reference

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

10.2337/db08-1193 · 2009 · External reference

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

10.1016/j.jacc.2008.10.033 · 2009 · External reference

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection

10.1016/j.molmet.2014.04.009 · 2014 · External reference

The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia

10.1007/bf01270577 · 1992 · External reference

Energy metabolism of the heart: from basic concepts to clinical applications

10.1016/0146-2806(94)90008-6 · 1994 · External reference

Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes

10.1161/01.cir.89.2.793 · 1994 · External reference

Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection

10.1161/circulationaha.107.697979 · 2008 · External reference

Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial

2012 · External reference

Diabetes, incretin hormones and cardioprotection

10.1136/heartjnl-2012-303242 · 2014 · External reference

Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress

10.1161/circulationaha.107.691253 · 2007 · External reference

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

10.1152/ajpheart.00347.2005 · 2005 · External reference

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

10.1016/s0196-9781(03)00108-6 · 2003 · External reference

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

10.1186/1475-2840-12-154 · 2013 · External reference

Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart

10.1371/journal.pone.0130894 · 2015 · External reference

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

10.1152/ajpheart.00930.2009 · 2010 · External reference

Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization

10.1016/j.jcin.2014.09.014 · 2015 · External reference

Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia

10.1371/journal.pone.0083758 · 2014 · External reference

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

10.1161/01.cir.74.5.1124 · 1986 · External reference

Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial

10.1161/circulationaha.108.809723 · 2009 · External reference

Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up

10.1161/circinterventions.112.000184 · 2013 · External reference

The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning

10.1016/j.tcm.2005.03.001 · 2005 · External reference

Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine

10.1016/j.cardiores.2005.02.015 · 2005 · External reference

Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection

10.1161/01.res.81.6.1072 · 1997 · External reference

Remote preconditioning reduces ischemic injury in the explanted heart by a KATP channel-dependent mechanism

10.1152/ajpheart.00207.2004 · 2005 · External reference

The mitochondrial permeability transition pore as a target for preconditioning and postconditioning

10.1007/s00395-009-0010-x · 2009 · External reference

Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury

10.1016/j.cardiores.2003.09.025 · 2003 · External reference

GLP-1 and cardioprotection: from bench to bedside

10.1093/cvr/cvs123 · 2012 · External reference

Mechanisms of action of glucagon-like peptide 1 in the pancreas

10.1016/j.pharmthera.2006.11.007 · 2007 · External reference

An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury

10.1152/ajpheart.00835.2014 · 2015 · External reference

ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases

10.1152/ajpheart.00474.2002 · 2002 · External reference

Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage

10.1161/01.cir.87.1.208 · 1993 · External reference

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

10.1016/j.abb.2008.08.001 · 2008 · External reference

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

10.1152/ajpendo.00373.2007 · 2007 · External reference

Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment

10.1152/ajpendo.00473.2012 · 2013 · External reference

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat

10.1016/s0167-0115(01)00300-7 · 2001 · External reference

GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans

10.1042/cs20130708 · 2014 · External reference

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes

10.2337/dc14-1958 · 2015 · External reference

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

10.1136/bmjopen-2012-001986 · 2013 · External reference

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

10.1016/s0140-6736(10)60307-8 · 2010 · External reference

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

10.1136/hrt.2010.219345 · 2012 · External reference

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

10.1186/s12933-015-0259-3 · 2015 · External reference

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

10.1161/circimaging.109.899377 · 2010 · External reference

Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease

10.1161/circimaging.113.000785 · 2014 · External reference

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

10.1161/circinterventions.110.960476 · 2011 · External reference

Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humans

10.1093/eurjhf/hfp040 · 2009 · External reference

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

10.1016/j.cardfail.2006.08.211 · 2006 · External reference

Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1

10.1161/hc4801.100038 · 2001 · External reference

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

10.1093/eurheartj/ehr309 · 2012 · External reference

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

10.1161/circinterventions.112.968388 · 2012 · External reference

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study

10.1161/atvbaha.113.301586 · 2013 · External reference

10.1016/j.jacc.2015.08.914

10.1016/j.jacc.2015.08.914 · External reference

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

10.1016/j.amjcard.2007.05.022 · 2007 · External reference

Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study

10.1053/j.jvca.2013.06.021 · 2014 · External reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

10.1056/nejmoa1307684 · 2013 · External reference

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

10.1056/nejmoa1305889 · 2013 · External reference

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

10.1056/nejmoa1501352 · 2015 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Cardioprotection for percutaneous coronary intervention—reperfusion quality as well as quantity

10.1016/j.ijcard.2014.10.041 · 2014 · External reference

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

10.1161/01.cir.0000120505.91348.58 · 2004 · External reference